830346-46-8

Usage

Uses

Used in Organic Synthesis:
1-(2-FLUORO-6-(TRIFLOROMETHYL)BENZYL)UREA is used as an organic synthesis intermediate for the preparation of various complex organic molecules. Its unique structure allows for selective reactions and modifications, facilitating the synthesis of target compounds with desired properties.
Used in Pharmaceutical Industry:
1-(2-FLUORO-6-(TRIFLOROMETHYL)BENZYL)UREA is used as a pharmaceutical intermediate, playing a crucial role in the development of new drugs. Its specific chemical features can be exploited to design and synthesize pharmaceutically active compounds, potentially leading to the discovery of novel therapeutic agents.
Used in Laboratory Research and Development:
1-(2-FLUORO-6-(TRIFLOROMETHYL)BENZYL)UREA is utilized in laboratory settings for research and development purposes. Its unique chemical properties make it a valuable tool for studying various chemical reactions and processes, contributing to the advancement of scientific knowledge and the development of new technologies.
Used in Chemical Production Processes:
1-(2-FLUORO-6-(TRIFLOROMETHYL)BENZYL)UREA is employed in chemical production processes, where it serves as a key component in the synthesis of various chemical products. Its presence in these processes can enhance the efficiency and yield of the final products, making it an important asset in the chemical industry.

Synthesis

In a 250 ml three-necked flask, 3.4 g of E6, 20 ml of water, 4.23 g of urea, and hydrochloric acid (12 mol / L, 2 ml) were added. After refluxing for 3 hours, the reaction solution was cooled to 4 ° C with an ice water bath, and filtered to obtain 3.78 g of a white solid ( Yield: 91%).

InChI:InChI=1/C9H8F4N2O/c10-7-3-1-2-6(9(11,12)13)5(7)4-15-8(14)16/h1-3H,4H2,(H3,14,15,16)

Upstream product

• 60611-24-7 2-fluoro-6-(trifluoromethyl)benzaldehyde 
• 57-13-6 urea 
• 239087-08-2 2-(bromomethyl)-1-fluoro-3-(trifluoromethyl)benzene 
• 590-28-3 potassium cyanate 
• 643088-07-7 2-fluoro-6-(trifluoromethyl)benzylamine hydrochloride 
• 401-80-9 3-fluoro-trifluoromethylbenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 133116-83-3 2-fluoro-6-(trifluoromethyl)benzonitrile 
• 239087-06-0 (2-fluoro-6-(trifluoromethyl) phenyl)methanamine 

Downstream Products

• 830346-47-9 1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-2,4(1H,3H)-pyrimidinedione 
• 1150560-59-0 5-(2-fluoro-3-methoxyphenyl)-1-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-6-methylpyrimidine-2,4(1H,3H)-dione 
• 830346-50-4 3-[(2R)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-2,4(1H,3H)-pyrimidinedione trifluoroacetate 
• 834153-87-6 4-((R)-2-[5-(2- fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl ]-1- phenylethylamino)-butyric acid 
• 830346-48-0 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4-(1H,3H)-dione 
• 830346-51-5 (R)-(2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)carbamic acid tert-butyl ester 
• 830346-49-1 {(R)-2-[5-bromo-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 869984-36-1 C₄₂H₄₉F₄N₃O₇ 
• 869984-33-8 C₃₇H₃₉F₄N₃O₇ 
• 869984-35-0 C₃₃H₃₈BrF₄N₃O₇ 
• 869984-32-7 C₃₃H₃₃F₄N₃O₅ 
• 869984-31-6 C₃₄H₃₅F₄N₃O₅ 
• 869984-48-5 C₂₈H₂₇BrF₄N₄O₅ 
• 869984-34-9 C₂₇H₂₈BrF₄N₃O₅ 

Relevant academic research and scientific papers

Preparation method of olagolide intermediate

The present invention relates to a method for preparing a lacolagoli intermediate 5-bromo-1- {[2-fluoro-6-(trifluoromethyl)phenyl] methyl}-6-methyl-2,4 (1H, 3H) pyrimidinedione (compound of formula I), in particular, a compound of formula III with 2-fluor

Ammonium Chloride-Promoted Rapid Synthesis of Monosubstituted Ureas under Microwave Irradiation

Monosubstituted ureas are important scaffolds in organic chemistry. They appear in various biologically active compounds and serve as versatile precursors in synthesis. Monosubstituted ureas were originally prepared using toxic and hazardous phosgene equivalents. Modern methods include transamidation of urea and nucleophilic addition to cyanate salts, both of which suffer from a narrow substrate scope due to the need for a strong acid and prolonged reaction times. We hereby report that ammonium chloride can promote the reaction between amines and potassium cyanate to generate monosubstituted ureas in water. This method proceeds rapidly under microwave irradiation and tolerates a broad range of functional groups. Unlike previous strategies, it is compatible with other nucleophiles, acid-labile moieties, and most of the common protecting groups. The products precipitate out of solution, allowing facile isolation without column chromatography.

Elagolix Sodium Compositions and Processes

The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof.

Preparation method of oxlagrel intermediate

The invention relates to a preparation method of an oxlagrel intermediate. The preparation method comprises the following steps: dissolving a 2-fluoro-6-(trifluoromethyl)benzyl bromide compound 7 in an aprotic polar solvent, then adding alkali carbonate and urea, carrying out a heating reaction under stirring, and after the reaction is finished, carrying out post-treatment and recrystallization toobtain a compound 4, the yield being 89-95 wt%; and dissolving the compound 4 prepared in the step (1) into the aprotic polar solvent; then, adding a 2-bromoacetoacetic acid ethyl ester compound 9, and cooling to 3 DEG C or below, adding bromo-organosilane while stirring, then continuing to stir and react at 80 DEG C or below, and after the reaction is finished, carrying out aftertreatment and recrystallization to obtain the target product 5-bromo-1-(2-fluoro-6-trifluoromethylbenzyl)-6-methylpyrimidine (1H, 3H)-2,4-diketone compound 1, the yield being 75-88 wt%. The method is simple in synthetic route and simple and convenient in post-treatment mode.

Substituted pyrimidine-2, 4(1H, 3H)-dione derivative and uses thereof

The invention belongs to the technical field of medicines, and relates to a substituted pyrimidine-2, 4(1H, 3H)-dione derivative and uses thereof, and a pharmaceutical composition containing the compound. The derivative and the pharmaceutical composition can be used as gonadotropin releasing hormone receptor antagonists. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and uses of the compound and the pharmaceutical composition in prevention or treatment of sex hormone dependent diseases including but not limited to prostate cancer, endometriosis, hysteromyoma, precocious puberty and the like.

Preparation method of C13H10F4N2O2

The invention discloses a preparation method of C13H10F4N2O2 and relates to the field of compound production. The preparation method includes: S1, adding urea to distilled water to prepare a mixture IM C, and adding the mixture IM C to a reaction kettle a

Preparation method of 1-(2-fluoro-6-(trifluoromethyl)benzyl)urea

The invention discloses a preparation method of 1-(2-fluoro-6-(trifluoromethyl)benzyl)urea. The preparation method comprises the following steps: reducing a compound 2-fluoro-6-(trifluorophenyl)cyanophenyl into a compound (2-fluoro-6-(trifluoromethyl)benzyl)tert-butyl carbamate through a reducing agent under the condition that a catalyst and di-tert-butyl dicarbonate participate; and then reactingthe compound (2-fluoro-6-(trifluoromethyl)benzyl)tert-butyl carbamate with urea in a hydrochloric acid solution to obtain a key intermediate compound 1-(2-fluoro-6-(trifluoromethyl)benzyl)urea of elagolix. The method has the beneficial effects of avoidance of the use of toxic reagents, mild reaction conditions, low cost, high yield, simplified route, and suitability for industrial large-scale production.

Method for preparing intermediate of elagolix

The invention relates to a method for preparing an intermediate of elagolix. In particular, the invention discloses a method for preparing a key intermediate compound E8 of elagolix, and compounds such as a compound E4 for preparing the intermediate compound E8. The method is simple and convenient in operation, mild in condition and very applicable to industrial production.

Method for preparing agomelatine intermediate (by machine translation)

The invention relates to a method for preparing an intermediate of agomelatine. The method is simple and convenient to E8 operate, mild E8 in condition and very suitable for industrial production C. (by machine translation)

Method for preparing GnRHR drug key intermediate compound

The invention discloses a method for preparing a GnRHR drug key intermediate compound. According to the invention, a synthetic route of the GnRHR drug key intermediate is changed, and meanwhile, a boron hydrogen salt is taken as a reducing agent and a chl